NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 218 filers reported holding NEVRO CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,733,834 | -42.5% | 246,275 | -24.0% | 0.00% | -33.3% |
| Q2 2023 | $8,234,567 | -37.1% | 323,937 | -10.5% | 0.00% | -25.0% |
| Q1 2023 | $13,087,037 | +540686.7% | 362,023 | +492.1% | 0.00% | +300.0% |
| Q4 2022 | $2,420 | -99.6% | 61,140 | +383.5% | 0.00% | – |
| Q2 2022 | $554,000 | -90.3% | 12,646 | -84.0% | 0.00% | -100.0% |
| Q1 2022 | $5,716,000 | -47.3% | 79,032 | -40.9% | 0.00% | -33.3% |
| Q4 2021 | $10,850,000 | -24.8% | 133,832 | +8.0% | 0.00% | -40.0% |
| Q3 2021 | $14,422,000 | -3.1% | 123,920 | +38.1% | 0.01% | 0.0% |
| Q2 2021 | $14,880,000 | +43.2% | 89,751 | +20.5% | 0.01% | +66.7% |
| Q1 2021 | $10,389,000 | +167.3% | 74,476 | +231.7% | 0.00% | +200.0% |
| Q4 2020 | $3,887,000 | +36.5% | 22,454 | +9.9% | 0.00% | 0.0% |
| Q3 2020 | $2,847,000 | +53.6% | 20,435 | +31.7% | 0.00% | 0.0% |
| Q2 2020 | $1,854,000 | +9.6% | 15,520 | -8.2% | 0.00% | 0.0% |
| Q1 2020 | $1,691,000 | – | 16,911 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |